Rani Therapeutics Holdings, Inc. Class A ( (RANI) ) has released its Q3 earnings. Here is a breakdown of the information Rani Therapeutics Holdings, Inc. Class A presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing technologies for oral delivery of biologics and drugs, aiming to provide a convenient alternative to injections. The company operates primarily in the healthcare sector, with its unique RaniPill capsule technology designed to deliver a variety of drug substances orally.
In its latest earnings report, Rani Therapeutics highlighted a challenging financial period with a net loss of $31.9 million for the nine months ended September 30, 2025. The company reported a decrease in operating expenses compared to the previous year, yet continues to face significant financial hurdles as it advances its RaniPill technology.
Key financial metrics indicate that Rani Therapeutics experienced a reduction in research and development expenses from $19.9 million to $15.3 million year-over-year, and general administrative expenses also decreased. Despite these reductions, the company’s total assets fell significantly from $36.6 million to $10.1 million, largely due to reduced cash reserves and marketable securities.
Looking ahead, Rani Therapeutics is focused on strategic financing opportunities and collaborations, such as its agreement with Chugai Pharmaceuticals, to support its operations and development of the RaniPill capsule. The company remains optimistic about its ability to secure necessary funding and partnerships to continue its innovative work in drug delivery technology.
Rani Therapeutics’ management remains committed to advancing its technology and exploring new opportunities for growth, while acknowledging the financial challenges that lie ahead. The company is poised to leverage its unique platform to potentially transform drug delivery methods in the healthcare industry.